Article citationsMore>>

Inoue, K., Ninomiya, J., Saito, T., Okubo, K., Nakakuma, T., Yamada, H., et al. (2019) Eribulin, Trastuzumab, and Pertuzumab as First-Line Therapy for Patients with HER2-Positive Metastatic Breast Cancer: A Phase II, Multicenter, Collaborative, Open-Label, Single-Arm Clinical Trial. Investigational New Drugs, 37, 538-547.
https://doi.org/10.1007/s10637-019-00755-x

has been cited by the following article:

• TITLE: Drug-Drug Interactions in Patients with Breast Cancer

  AUTHORS: Balaram Gudapati, Terry Oroszi

  KEYWORDS: Breast Cancer, Drug-Drug Interactions, Polypharmacy, Side Effects, Anti-Cancer Drug Failure, Complementary and Alternative Medicine

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.9, September 11, 2024

  ABSTRACT: The research paper investigates the intricate landscape of drug-drug interactions (DDIs) within the context of breast cancer treatment, with a particular focus on the elderly population and the use of complementary and alternative medicine (CAM). The study underscores the heightened susceptibility of elderly patients to DDIs due to the prevalence of polypharmacy and the widespread utilization of CAM among breast cancer patients. The potential ramifications of DDIs, encompassing adverse drug events and diminished treatment efficacy, are elucidated. The paper accentuates the imperative for healthcare providers to comprehensively understand both conventional and CAM therapies, enabling them to provide patients with informed guidance regarding safe and efficacious treatment options, culminating in enhanced patient outcomes.